BD PROJECTS
Product for Licensing
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team (Email: BD@drugtimes.cn)
Request for Product
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team
If you are interested in these opportunities, please feel free to contact DrugTimes BD Team
If you are interested in this opportunity, please contact DrugTimes BD Team by email (BD@drugtimes.cn)
If you are interested in this opportunity, please contact DrugTimes BD Team by email (BD@drugtimes.cn)
If you are interested in this opportunity, please contact DrugTimes BD Team by email (BD@drugtimes.cn)
If you are interested in this opportunity, please contact DrugTimes BD Team by email (BD@drugtimes.cn).
Driven by the rising prevalence of eye diseases and increased public awareness of healthca…
Semaglutide, a GLP-1 receptor agonist, can truly be described as a “breakout star…
On July 9, 2025, Novartis struck another deal, acquiring Sironax’s “Brain Deli…
Bio News
【DrugTimes Comments】 As the exclusive BD advisor to SiranBio, the DrugTimes BD Team is hon…
For more DrugTimes bio-news, please follow DrugTimes. Many thanks!
For more bio-news, please follow DrugTimes. Many thanks!
We cordially invite you to join us live on May 17 as we work together to accelerate the globalization of China’s innovative drugs. See you online!
For more reports, please follow DrugTimes
Congratulations to Dr. Tie-Ling Wang and VastPro PharmaTech!
DrugTimes will continue to follow up and report in a timely manner
Johnson & Johnson gains an exclusive license to Kaken’s STAT6 program, including lead candidate KP-723
DrugTimes Team will keep updating this document in the coming days. All comments are highly welcome!~
Novo Nordisk still expects the acquisition to be completed towards the end of 2024
Congratulations to GSK and Vesalius Therapeutics!
Congratulations to CSPC and AstraZeneca!
Insights
DrugTimes BD Team has contributed to successful deals with a total value of US$2.3B
DrugTimes BD Team has contributed to successful deals with a total value of US$2.3B
On August 5, 2025, XtalPi Inc. entered into a collaboration agreement with Dovetree (a com…
Vertex Pharmaceuticals faces renewed setbacks in its non-opioid analgesic pipeline. Its Na…
On August 5, 2025, Robert F. Kennedy Jr., the newly appointed U.S. Secretary of Health and…
On August 1, 2025, local time, Allogene Therapeutics (hereinafter referred to as “Al…
August 2, 2025 – The clinical trial application for SNC115, a DLL3-targeting chimeric anti…
During the Q2 earnings call, when asked whether Moderna was considering M&A deals in C…
On July 17, 2025, a landmark achievement was made in the “world’s first”…
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
DrugTimes team will continue to follow and report. Please stay tuned. Many thanks!
